FTO Mutation Hijacks Cellular Stress Pathways Linked to Cancer and Protein Homeostasis
A V493F mutation in the FTO demethylase protein dysregulates ERAD and stress response proteins in neuroblastoma cells, independent of enzymatic activity.
Résumé
Researchers at Kocaeli University introduced the obesity-linked V493F mutation into the FTO protein and expressed it in SH-SY5Y neuroblastoma cells. Using 2D gel electrophoresis and MALDI-TOF/TOF mass spectrometry, they compared proteomes of mutant vs. wild-type FTO-overexpressing cells. Wild-type FTO overexpression primarily altered DNA replication and repair proteins like PCNA. By contrast, the V493F mutation shifted expression toward stress response and endoplasmic reticulum-associated degradation (ERAD) pathway proteins, notably downregulating VCP and ARHGDIA while upregulating HSPA4. Crucially, the mutation did not change FTO's nuclear localization or predicted 3D structure, suggesting these proteomic effects arise from disrupted protein-protein interactions in the C-terminal domain rather than altered catalytic activity. These findings implicate FTO in protein homeostasis regulation and suggest its mutations may contribute to cancer-relevant pathway dysregulation.
Résumé détaillé
The FTO protein is a well-known RNA demethylase implicated in obesity, cancer, and neurological disease, yet the function of its C-terminal domain (CTD) remains poorly understood compared to other AlkB homologs. This study focused on V493F, a naturally occurring exonic variant found exclusively in obese individuals in prior screening studies, which was previously shown not to impair FTO's in vitro demethylase activity. The central question was whether this CTD mutation might alter FTO's non-catalytic cellular functions — particularly its ability to interact with protein partners.
To investigate this, researchers generated stable SH-SY5Y neuroblastoma cell lines using a tetracycline-inducible system to overexpress either wild-type (WT-FTO) or mutant (V493F-FTO) protein. Three independent clones per group were used to ensure reproducibility. Comparative proteomics via 2D gel electrophoresis resolved over 500 protein spots per gel, with 10 spots showing ≥2-fold differential expression. Protein identities were confirmed by MALDI-TOF/TOF mass spectrometry and validated by western blotting, including specific confirmation of VCP downregulation.
WT-FTO overexpression altered four proteins linked primarily to DNA replication, cell cycle control, and nucleotide excision repair — notably downregulating PCNA and YWHAZ (14-3-3ζ). In striking contrast, V493F-FTO overexpression altered six proteins concentrated in the ERAD pathway and cellular stress response: HSPA4, DCAF7, RANBP1, and ACTB were upregulated, while ARHGDIA and VCP (valosin-containing protein/TERA) were downregulated. STRING network analysis confirmed that VCP, a central AAA-ATPase in ERAD, is a hub for retrograde ER-to-cytosol protein transport and ubiquitin-dependent degradation of misfolded proteins. HSPA4 and VCP together were linked to proteotoxic stress responses.
Importantly, immunofluorescence microscopy confirmed that V493F-FTO retains nuclear localization identical to WT-FTO, and Swiss-Model homology modeling showed no gross structural differences in the predicted 3D fold. This rules out mislocalization or global misfolding as explanations and instead points toward disrupted CTD-mediated protein-protein interactions — perhaps similar to how zinc finger proteins like ZBTB48 recruit FTO to specific RNA substrates.
The clinical implications are notable: VCP mutations are linked to multiple degenerative diseases and cancer, while dysregulation of HSPA4 and ERAD pathways underpins therapeutic resistance in multiple tumor types. FTO itself is overexpressed in numerous cancers. This study suggests that CTD mutations in FTO can rewire protein homeostasis networks in ways that could promote oncogenesis or stress adaptation, positioning FTO's CTD as a potentially targetable domain independent of its demethylase activity.
Principales conclusions
- V493F-FTO overexpression downregulated VCP and ARHGDIA, disrupting ERAD and Rho GTPase signaling pathways.
- HSPA4 (a stress chaperone) was significantly upregulated by V493F-FTO, indicating activated proteotoxic stress response.
- WT-FTO overexpression primarily affected DNA repair proteins including PCNA, distinct from V493F effects.
- V493F mutation did not alter FTO's nuclear localization or predicted 3D protein structure.
- Effects appear independent of FTO demethylase activity, implicating CTD-mediated protein interactions.
Méthodologie
Stable SH-SY5Y neuroblastoma cell lines expressing WT or V493F FTO under tetracycline-inducible control were used across three independent clones per group. Comparative proteomics employed 2D gel electrophoresis (pH 3-10, 12% SDS-PAGE) with colloidal Coomassie staining, and differentially expressed spots were identified by MALDI-TOF/TOF mass spectrometry with MASCOT database matching (p<0.005). Western blotting and STRING network analysis were used for validation and pathway contextualization.
Limites de l'étude
The study used a single neuroblastoma cell line (SH-SY5Y), limiting generalizability to other cancer types or primary cells. The proteomic approach detected only soluble proteins, potentially missing membrane-associated or low-abundance interaction partners. Causal mechanisms linking V493F to specific proteomic changes — particularly which protein-protein interactions are disrupted — were not directly tested.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :